Clinical Case Study: Targeting BCMA With ADCs in MM

Source: Corneal Toxicity in Patients Receiving Antibody–Drug Conjugates for the Treatment of Cancer
Download Slideset
Download this slideset based on the content from a live satellite symposium with a case study of the antibody–drug conjugate belantamab mafodotin and the potential for ocular toxicity while receiving this treatment for myeloma.
Paul G. Richardson, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 507 KB
Released: November 12, 2021

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
GlaxoSmithKline

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings